Analyst Tyler Van Buren expressed concern over the rapid dec...
Analyst Tyler Van Buren expressed concern over the rapid decline in efficacy of Moderna's vaccine, stating it could negatively affect the vaccine's profile if confirmed with additional data. He maintains a Market Perform rating and a $75 target on MRNA.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4080Followers
0Following
9086Visitors
Follow
EagleAlpha : When RSV combines with covid and flu shot, it won’t be a disadvantage to just cover one season. U will get 2-in-1 or 3-in-1 shot every year anyway. It’s sufficient and still a good vaccine, remember current flu shot last just 6 months with just 40-60% efficacy rate.